CAJ | 학술논문

随着新的靶向骨髓瘤药物的应用,初诊老年多发性骨髓瘤(multiple myeloma,MM)患者的中位生存期从30个月延长至60个月,但具有一些高危预后因素的老年患者临床结果仍欠佳.文章结合第19届欧洲血液学会年会相关报道,从标准治疗方案、治疗方式、预后因素三个方面对初诊老年MM患者的研究进展作一介绍.
수착신적파향골수류약물적응용,초진노년다발성골수류(multiple myeloma,MM)환자적중위생존기종30개월연장지60개월,단구유일사고위예후인소적노년환자림상결과잉흠가.문장결합제19계구주혈액학회년회상관보도,종표준치료방안、치료방식、예후인소삼개방면대초진노년MM환자적연구진전작일개소.
As the introduction of novel agents,the median overall survival of elderly newly diagnosed multiple myeloma patients has increased roughly from 30 to 60 months.But patients with high risk prognostic features still have a poor clinical outcome.This paper which combined the 19th annual congress of the European Hematology Association (EHA) reviews the advances in elderly patients with newly diagnosed multiple myeloma,including standard of care,the way to treatment and prognostic factors.